MbrlCatalogueTitleDetail

Do you wish to reserve the book?
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
Journal Article

The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial

2020
Request Book From Autostore and Choose the Collection Method
Overview
Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration using the well-established and safe combination of diethylcarbamazine and albendazole (DA) since 2002. In certain settings the addition of ivermectin to this combination (IDA) remains a safe strategy and is more efficacious. However, the safety has yet to be described in scabies and soil-transmitted helminth endemic settings like Fiji. Villages of Rotuma and Gau islands were randomised to either DA or IDA. Residents received weight-based treatment unblinded with standard exclusions. Participants were actively found and asked by a nurse about their health daily for the first two days and then asked to seek review for the next five days if unwell. Anyone with severe symptoms were reviewed by a doctor and any serious adverse event was reported to the Medical Monitor and Data Safety Monitoring Board. Of 3612 enrolled and eligible participants, 1216 were randomised to DA and 2396 to IDA. Age and sex in both groups were representative of the population. Over 99% (3598) of participants completed 7 days follow-up. Adverse events were reported by 600 participants (16.7%), distributed equally between treatment groups, with most graded as mild (93.2%). There were three serious adverse events, all judged not attributable to treatment by an independent medical monitor. Fatigue was the most common symptom reported by 8.5%, with headache, dizziness, nausea and arthralgia being the next four most common symptoms. Adverse events were more likely in participants with microfilaremia (43.2% versus 15.7%), but adverse event frequency was not related to the presence of scabies or soil-transmitted helminth infection. IDA has comparable safety to DA with the same frequency of adverse events experienced following community mass drug administration. The presence of co-endemic infections did not increase adverse events. IDA can be used in community programs where preventative chemotherapy is needed for control of lymphatic filariasis and other neglected tropical diseases.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject

Adolescent

/ Adult

/ Age

/ Aged

/ Aged, 80 and over

/ Albendazole

/ Albendazole - administration & dosage

/ Albendazole - adverse effects

/ Antiparasitic Agents - administration & dosage

/ Antiparasitic Agents - adverse effects

/ Arthralgia

/ Chemotherapy

/ Child

/ Child, Preschool

/ Combination drug therapy

/ Community

/ Community-Acquired Infections - drug therapy

/ Diethylcarbamazine

/ Diethylcarbamazine - administration & dosage

/ Diethylcarbamazine - adverse effects

/ Dosage and administration

/ Drug dosages

/ Drug therapy

/ Drug Therapy, Combination - adverse effects

/ Drug Therapy, Combination - methods

/ Drug-Related Side Effects and Adverse Reactions - epidemiology

/ Drug-Related Side Effects and Adverse Reactions - pathology

/ Drugs

/ Earth Sciences

/ Elephantiasis, Filarial - drug therapy

/ Female

/ Fiji

/ Filariasis

/ Frequency

/ Headache

/ Health services

/ Helminthiasis - drug therapy

/ Hospitals

/ Humans

/ Infant

/ Infections

/ Insecticides - administration & dosage

/ Insecticides - adverse effects

/ Islands

/ Ivermectin

/ Ivermectin - administration & dosage

/ Ivermectin - adverse effects

/ Male

/ Medicine and Health Sciences

/ Middle Aged

/ Nausea

/ Neglected Diseases - drug therapy

/ Patient outcomes

/ People and Places

/ Public health

/ Randomization

/ Research and Analysis Methods

/ Rural Population

/ Safety

/ Scabies

/ Scabies - drug therapy

/ Signs and symptoms

/ Software

/ Soil

/ Soils

/ Studies

/ Supervision

/ Symptoms

/ Therapy

/ Treatment Outcome

/ Tropical climate

/ Tropical diseases

/ Vector-borne diseases

/ Young Adult